Innovative Clinical Trial Designs — Welcomed By Regulators But What About The Payers?

April 25, 2018

There is a well-recognized long-standing decline in R&D productivity in the pharmaceutical industry which has driven exploration of new approaches to the clinical development of pharmaceuticals (Scannell, 2012). These include innovative randomized controlled trial designs, such as adaptive, umbrella, basket, and pragmatic studies.

There will be pragmatic attitudes amongst payers regarding the use of innovative clinical trial designs however there will also be skepticism; for many HTA bodies this is new and uncertain territory.

Previous Article
4 Ways to Align Real-World Data & Stakeholder Needs
4 Ways to Align Real-World Data & Stakeholder Needs

Next Flipbook
Presentation Slides: Early Engagement Strategies Webinar
Presentation Slides: Early Engagement Strategies Webinar

×

Speak to one of our experts today

First Name
Last Name
Company Name
Title
Country
Tell us how we can help
We'll be in touch shortly!
Error - something went wrong!